Please assess the completion status of the following clinical trial:

Trial Title: Astaxanthin for Management of Inflammation in Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age~* Radiographic evidence of advanced knee osteoarthritis~* Knee pain~* Scheduled to undergo a total knee replacement~Exclusion Criteria:~* \< 18 years of age~* Unable to provide written consent~* Known allergy to fish or astaxanthin~* Pregnant and/or breastfeeding~* Received a corticosteroid injection within 3 months of initiating treatment with astaxanthin or placebo~* Currently taking immunosuppressants~* Patients with known autoimmune etiology for arthritis (e.g. Rheumatoid or Psoriatic arthritis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Control: Placebo Group (Type: PLACEBO_COMPARATOR): Patients will receive a 6 week daily oral supply of placebo, identical in appearance to the astaxanthin supplement.
- Experimental: Astaxanthin Supplementation Group (Type: ACTIVE_COMPARATOR): Patients will receive a 6 week daily oral supply of 12 mg astaxanthin supplement.

Based on this trial design, predict the completion outcome and termination type (if applicable).